Welcome to our dedicated page for ICON PLC news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on ICON PLC stock.
ICON PLC (ICLR) delivers essential clinical research services across 100+ countries, supporting pharmaceutical and biotechnology development through all trial phases. This news hub provides investors and industry professionals with timely updates on operational milestones, financial performance, and strategic initiatives shaping global drug development.
Access authoritative reporting on regulatory submissions, partnership announcements, and clinical trial advancements directly impacting ICON's market position. Our curated feed eliminates information fragmentation by centralizing earnings calls, governance updates, and technology implementations critical for evaluating contract research organizations.
Key coverage areas include phase III trial initiations, FDA/EMA regulatory interactions, acquisition strategies, and capacity expansion projects. Bookmark this page for real-time updates on ICON's patient recruitment innovations and quality control enhancements that maintain compliance with evolving global standards.
LEO Pharma and ICON plc (NASDAQ: ICLR) have announced a strategic partnership aimed at enhancing patient-centric clinical trial execution. This initiative, dubbed PACE, seeks to address current clinical development challenges by improving access to innovative dermatology treatments. The partnership will utilize a hybrid outsourcing model, allowing for scalable efficiencies in clinical trials, decentralized clinical trials, and leveraging ICON's extensive resources. This collaboration aligns with LEO Pharma's 2030 strategy, focusing on delivering treatments faster and supporting sustainable business practices.
ICON plc (NASDAQ: ICLR), a leading clinical research organization, announced that CFO Brendan Brennan will present at the 2023 Citi Healthcare Conference on March 2, 2023, at 2pm ET. Additionally, CEO Steve Cutler will present at the Barclays Global Healthcare Conference on March 15, 2023, starting at 1:35pm ET. Both presentations will be available via live webcast, with links posted on ICON's investor relations website. As of December 31, 2022, ICON employed approximately 41,100 staff across 111 locations in 53 countries, focused on advancing clinical research for various healthcare sectors.
ICON plc (NASDAQ: ICLR) reported robust financial results for Q4 2022 and the full year, showcasing strong operational performance. Net business wins were $2,350 million in Q4, with a record backlog of $20.7 billion, reflecting a 2.4% quarterly increase. Q4 revenue reached $1,962 million, a 4.3% rise from the previous year. Full-year revenue was $7,741.4 million, a significant 41.2% growth. Adjusted EBITDA for Q4 was $405 million, marking a 21.8% increase, while GAAP net income for the full year amounted to $505.3 million, translating to $6.13 per diluted share. The company reaffirmed its 2023 revenue guidance of $7,940 - $8,340 million.
ICON (NASDAQ: ICLR), a leading healthcare intelligence and clinical research organization, will release its financial results for Q4 2022 on February 22, 2023, after market close. A conference call to discuss the results will be held on February 23, 2023, at 8:00 am ET. The company, headquartered in Dublin, Ireland, employed approximately 41,150 employees across 113 locations in 53 countries as of September 30, 2022. Investors are advised that this release contains forward-looking statements subject to risks and uncertainties, and should not rely solely on them for investment decisions.
ICON plc (ICLR) has announced its financial guidance for the year ending December 31, 2023. Expected revenue ranges from
ICON plc (NASDAQ: ICLR), a leader in healthcare intelligence and clinical research, announced that CEO Dr. Steve Cutler will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 5:15 PM PST/8:15 PM EST. The conference will showcase key insights into ICON's operations and strategy. Changes to the event will be updated on the Investor Relations section of their website under 'Events'. With approximately 41,150 employees across 113 locations in 53 countries, ICON is committed to advancing clinical research and improving patient lives.
On November 28, 2022, BetterInvesting Magazine announced Icon PLC (NYSE: ICLR) as its "Stock to Study" and Williams-Sonoma Inc. (NYSE: WSM) as its "Undervalued Stock" for the January-February 2023 issue. The initiative is aimed at enhancing investors' financial literacy and empowering informed investment decisions. BetterInvesting encourages potential investors to conduct thorough reviews using their online tools. The recommendations serve purely educational purposes and do not constitute endorsements for purchase.
ICON plc (NASDAQ: ICLR), a global leader in healthcare intelligence and clinical research, announced that CFO Brendan Brennan will present at the 2022 Evercore ISI HealthCONx Conference on November 30, 2022, at 08:00 am EST. The presentation will be available via live webcast. For updates and links to the webcast, visit the Investor section of ICON's website under 'Events'. As of September 30, 2022, ICON employed around 41,150 people across 113 locations in 53 countries, enhancing clinical research and patient care.
ICON plc (NASDAQ: ICLR) reported third quarter 2022 results showcasing strong financial performance. Net business wins reached $2,351 million, with a book-to-bill ratio of 1.21. Revenue for Q3 was $1,942.4 million, up 3.9% year-on-year. Year-to-date revenue hit $5,779.4 million, reflecting a 60.6% increase. Adjusted EBITDA stood at $379.6 million, representing 19.5% of revenue. Adjusted net income was $247.2 million, leading to $3.00$7,690 - $7,810 million.
FAQ
What is the current stock price of ICON PLC (ICLR)?
What is the market cap of ICON PLC (ICLR)?
